Neeraj Agarwal, MD, Huntsman Cancer Institute

Articles by Neeraj Agarwal, MD, Huntsman Cancer Institute

Future of Treating mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Treating Patients With mRCC Beyond Second-Line

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Strategies for Switching From Frontline Therapy to Second-Line Therapy in mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Clinical Trials Shaping Treatment in Relapsed/Refractory mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Choosing Second-Line Therapy in Treatment of mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Tailored Therapy Approaches for Upfront mRCC Treatment

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Treating Side Effects of Therapy for mRCC with Steroids

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Evaluating Safety Profiles of Upfront Regimens for mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Choosing Upfront Therapy for mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

CheckMate 9ER: Phase 3 Trial of Frontline Nivolumab + Cabozantinib

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Evaluating Long-Term Follow-Up Data for Treatment of mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Patient Factor Consideration for Treatment of mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Applying Clinical Trial Data for Treatment of mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Clinical Trials Defining the NCCN Guidelines for Frontline Treatment of mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Evaluation of Risk for Frontline Advanced/Metastatic Clear Cell RCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Latest Updated Articles

Clinical Trials Defining the NCCN Guidelines for Frontline Treatment of mRCC
July 23rd 2020
$Clinical Trials Shaping Treatment in Relapsed/Refractory mRCC$
Clinical Trials Shaping Treatment in Relapsed/Refractory mRCC
July 23rd 2020
Tailored Therapy Approaches for Upfront mRCC Treatment
July 23rd 2020
Patient Factor Consideration for Treatment of mRCC
July 23rd 2020
Future of Treating mRCC
July 23rd 2020
Evaluation of Risk for Frontline Advanced/Metastatic Clear Cell RCC
July 23rd 2020

Neeraj Agarwal, MD, Huntsman Cancer Institute

Articles by Neeraj Agarwal, MD, Huntsman Cancer Institute

Future of Treating mRCC

Treating Patients With mRCC Beyond Second-Line

Strategies for Switching From Frontline Therapy to Second-Line Therapy in mRCC

Clinical Trials Shaping Treatment in Relapsed/Refractory mRCC

Choosing Second-Line Therapy in Treatment of mRCC

Tailored Therapy Approaches for Upfront mRCC Treatment

Treating Side Effects of Therapy for mRCC with Steroids

Evaluating Safety Profiles of Upfront Regimens for mRCC

Choosing Upfront Therapy for mRCC

CheckMate 9ER: Phase 3 Trial of Frontline Nivolumab + Cabozantinib

Evaluating Long-Term Follow-Up Data for Treatment of mRCC

Patient Factor Consideration for Treatment of mRCC

Applying Clinical Trial Data for Treatment of mRCC

Clinical Trials Defining the NCCN Guidelines for Frontline Treatment of mRCC

Evaluation of Risk for Frontline Advanced/Metastatic Clear Cell RCC

Latest Updated Articles

Trending on OncLive

HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA

TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC

Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis

SERENA-6 Meets PFS2 End Point With Early Switch to Camizestrant in ER+/HER2-Negative, ESR1-Mutated Advanced Breast Cancer

Dr Eads on Early Data for CDH17-Directed CAR T-Cell Therapy in R/R GI Cancers